EFFICACY OF FIRST LINE ERADICATION THERAPY IN TREATMENT NAÏVE PATIENTS WITH HELICOBACTER PYLORI INFECTION
Main Article Content
Keywords
Helicobacter pylori, efficacy, eradication, first line eradication therapy
Abstract
Introduction: Helicobacter pylori (HP) is a well-recognized cause of peptic ulcer disease and is also linked to gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. Despite decades of research, determining the most effective eradication regimen remains a challenge.
Objective: To evaluate the efficacy of first-line H. pylori eradication regimens by assessing post-eradication stool antigen results among patients treated at a tertiary care hospital.
Methods: This descriptive cross-sectional study was conducted in the Department of Gastroenterology, Bolan Medical College, Quetta, over a six-month period from 26th September 2020 to 26th March 2021. A total of 113 patients who fulfilled the inclusion criteria were enrolled after obtaining informed consent. Detailed clinical histories were recorded, and stool samples were analyzed post-treatment to assess eradication efficacy. Results: Of the 113 participants, 71 (62.8%) were male and 42 (37.2%) female, showing male predominance. H. pylori infection was confirmed through histopathology in all cases (100%), while the rapid urease test showed no positive results. All patients received triple therapy as the first-line eradication regimen. Among them, 27 (23.9%) were smokers, 41 (36.3%) were obese, 33 (29.2%) were diabetic, and 36 (31.9%) were hypertensive. Post-eradication stool antigen testing revealed 97 (85.8%) negative and 16 (14.2%) positive results, indicating an eradication success rate of 85.8%. Conclusion: The study demonstrates that first-line triple therapy remains highly effective for H. pylori eradication in the local population and continues to be a suitable standard regimen in clinical practice.
References
2. Chuah YY, Wu DC, Chuah SK, Yang JC, Lee TH, Yeh HZ, et al. Real‐world practice and expectation of Asia‐Pacific physicians and patients in helicobacter pylori eradication (REAP‐HP Survey). Helicobacter. 2017 Jun;22(3):80.
3. Kim JS, Kim BW, Hong SJ, Kim JI, Shim KN, Kim JH, et al. Sequential therapy versus triple therapy for the first line treatment of helicobacter pylori in Korea: a nationwide randomized trial. Gut Liver. 2016;10:556–61.
4. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on helicobacter pylori gastritis. Gut. 2015;64:1353–67.
5. Yang JC, Lin CJ, Wang HL, Chen JD, Kao JY, Shun CT, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13:895–05.
6. Kefeli A, Basyigit S, Yeniova AO, Kefeli TT, Aslan M, Tanas O, et al. Comparison of three different regimens against helicobacter pylori as a first-line treatment: a randomized clinical trial. Bosnian J Basic Med Sci. 2016;16(1):52.
7. Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;18:647–54.
8. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 Sep 1;64(9):1353-67.
9. Mladenova I, Durazzo M. Transmission of Helicobacter pylori. Minerva gastroenterologica e dietologica. 2018 Sep;64(3):251-4.
10. Santacroce L. and Bhutani M. S. 2010. Helicobacter Pylori Infection. Medscape. Available from: http://emedicine.medscape.com/article/176938
11. Kawahara Y, Yokota K, Mizuno M, Yunoki N, Uesu T, Okada H, Kobayashi K, Hirai Y, Oguma K, Tsuji T. Antibodies to human gastric epithelial cells and heat shock protein 60 in Helicobacter pylori positive mucosa associated lymphoid tissue lymphoma. Gut. 1999 Jul 1;45(1):20-3.
12. Hage N, Renshaw JG, Winkler GS, Gellert P, Stolnik S, Falcone FH. Improved expression and purification of the Helicobacter pylori adhesin BabA through the incorporation of a hexa-lysine tag. Protein Expr Purif. 2015 Feb. 106:25-30.
13. Sverden E, Brusselaers N, Wahlin K, Lagergren J. Time latencies of Helicobacter pylori eradication after peptic ulcer and risk of recurrent ulcer, ulcer adverse events, and gastric cancer: a population-based cohort study. Gastrointest Endosc. 2018;88:242–250.e1.
14. Pajares JM, Gisbert JP. Helicobacter pylori: its discovery and relevance for medicine. Rev Esp Enferm Dig. 2006;98:770–785.
15. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH consensus development panel on Helicobacter pylori in peptic ulcer disease. JAMA. 1994;272:65–69.
16. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–1153.
17. Malfertheiner P, Megraud F, O’morain C, et al. Current European concepts in the management of Helicobacter pylori infection-the Maastricht Consensus Report. Eur J Gastroenterol Hepatol. 1997;9:1–2.
18. Gisbert JP, Calvet X, O’Connor A, Megraud F, O’Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010;44:313–325.
19. Kefeli A, Basyigit S, Yeniova AO, Kefeli TT, Aslan M, Tanas O, et al. Comparison of three different regimens against helicobacter pylori as a first-line treatment: a randomized clinical trial. Bosnian J Basic Med Sci. 2016;16(1):52.
20. Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;18:647–54.
21. Seven G, Cinar K, Yakut M, Idilman R, Ozden A. Assessment of Helicobacter pylori eradication rate of triple combination therapy containing levofloxacin. Turkish J Gastroenterol. 2011;22:582–586.
22. Telaku S, Manxhuka-Kerliu S, Kraja B, Qirjako G, Prifti S, Fejza H. The efficacy of levofloxacin-based triple therapy for first-line helicobacter pylori eradication. Med Archiv. 2013;67:348–350.
23. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14:1339–1343.
24. Antos D, Schneider‐Brachert W, Bästlein E, et al. 7‐day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high‐dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter. 2006;11:39–45.
25. Gisbert J, Fernandez‐Bermejo M, Molina‐Infante J, et al. First‐line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2007;26:495–500.
26. Gisbert JP, Bermejo MF, Infante JM, et al. Levofloxacin, amoxicillin, and omeprazole as first-line triple therapy for Helicobacter pylori eradication. J Clin Gastroenterol. 2009;43:384–385.
27. Schrauwen R, Janssen M, De Boer W. Seven-day PPI-triple therapy with levofloxacin is very effective for Helicobacter pylori eradication. Neth J Med. 2009;67:96–101.
28. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112:212.
29. O’Connor A, Taneike I, Nami A, et al. Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre. Ir J Med Sci. 2013;182:693–695.
30. Zullo A, Perna F, Hassan C, et al. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther. 2007;25:1429–1434.
31. Carabotti M, D’Ercole C, Iossa A, Corazziari E, Silecchia G, Severi C. Helicobacter pylori infection in obesity and its clinical outcome after bariatric surgery. World j Gastroenterol. 2014;20:647–653.
32. Osawa H. Ghrelin and Helicobacter pylori infection. World j Gastroenterol. 2008;14:6327–6333.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Muhammad Essa Khan
Bolan Medical Complex Hospital, Quetta, Balochistan, Pakistan
Safia Sana
Bolan Medical Complex Hospital, Quetta, Balochistan, Pakistan
Gulmina Kasi
Bolan Medical Complex Hospital, Quetta, Balochistan, Pakistan
Bahauddin
Bolan Medical Complex Hospital, Quetta, Balochistan, Pakistan
Asfandyar Khan
Sandeman Provincial Hospital, Quetta, Balochistan, Pakistan
Arifa Niamat
Sandeman Provincial Hospital, Quetta, Balochistan, Pakistan
Noman Ul Haq
Bolan Medical Complex Hospital, Quetta, Balochistan, Pakistan
Nisha Nisar
Bolan Medical Complex Hospital, Quetta, Balochistan, Pakistan
Samreen Sana
Bolan Medical Collage Quetta, Pakistan
Muhammad Kamran Taj
CASVAB, University of Balochistan, Pakistan